Grupo 1: Fisiopatología e Investigación Clínica de las Enfermedades de Base Inmunológica e Inflamatoria Crónicas
Código de grupo: 5.01
Tipo de grupo: Consolidado
Descripción del grupo: Fisiopatología e investigación clínica de las enfermedades de base inmunológica e inflamatoria crónicas.
Jefa de Grupo: Paloma Sánchez-Mateos Rubio
- Este grupo ha integrado a los investigadores del Grupo 5.04 Inmuno-Oncología que desaparece como tal.
| Integrantes del grupo | |
|---|---|
| Investigadores y personal de apoyo |
| ALONSO | ARMENDARIZ | ROCIO | First Stage Researcher |
| ARNAIZ | VILLENA | ANTONIO | Established Researcher |
| BALASTEGUI | MARTÍN | HÉCTOR | First Stage Researcher |
| BARRIO | ALONSO | CELIA | |
| DI NATALE | CIPRIANO | MARISA | First Stage Researcher |
| DIAZ | LUNA | MARIA MERCEDES | First Stage Researcher |
| ESTECHA | PALOMERO | ANA | Recognised Researcher |
| EZZAHOURI | EL KHALOUKI | IKRAM | First Stage Researcher |
| GARCIA | MARTINEZ | ELENA | First Stage Researcher |
| GIL | HERRERA | JUANA | Established Researcher |
| GOMEZ | PEREZ | JIMENA MARIA | First Stage Researcher |
| JUAREZ | MARTIN DELGADO | IGNACIO | |
| LOPEZ | NAVARRO | BALTASAR | |
| MARTIN | VILLA | JOSE MANUEL | Established Researcher |
| MARTINEZ | QUILES | NARCISA | Established Researcher |
| MEJIA | GONZALEZ | MARIA ALEJANDRA | First Stage Researcher |
| MONTANCHEZ | MATEO | JUDITH | |
| NAVARRO | CASPISTEGUI | JOAQUIN | Established Researcher |
| PEREZ | GARCIA | YAIZA | |
| PUIG | KRÖGER | AMAYA ROCIO | Established Researcher |
| RODRIGUEZ | SAINZ | MARIA CARMEN | Established Researcher |
| SAMANIEGO | GARCIA | RAFAEL | Recognised Researcher |
| SANCHEZ-MATEOS | RUBIO | PALOMA | Established Researcher |
| SANCHEZ | MARTIN | ALICIA | |
| SCHIAFFINO | GARCIA-VILLANOVA | MARIA TERESA | First Stage Researcher |
| TORRES | TORRESANO | MONICA |
| Líneas de Investigación | ||
|---|---|---|
| Axis 1. Immunotherapy with immunomodulatory agents in immunomediated pathologies.
L1: Immunomodulation of innate, adaptive and genetic responses with immunomodulatory agents in the treatment of immune-mediated diseases. Axis 2. Study of immunopathogenic mechanisms in: (2.1) Primary Immunodeficiencies and (2.2) Secondary to emerging virus infections (SARS-CoV2); (2.4) Immuno-oncology; (2.7) Autoimmune Chronic Inflammatory Diseases; (2.9) Reproductive Failures and (2.10) Solid Organ Transplantation. L1: Primary immunodeficiencies: immunopathogenesis, classification and treatment. L2: Study of specific memory T-cell responses to SARS-CoV2. L3: Biomarkers in secondary immunodeficiencies. L4: Cell migration in cancer. L5: Tumour macrophages in melanoma L6: Study of the efficacy of combining immunotherapy and radiotherapy in different human tumours. L7: Immunology of autoimmune chronic inflammatory diseases. L8: Role of macrophages in Autoimmune Inflammatory Diseases L9: Reproductive Immunology L10: Transplantation Immunology Axis 3: Immunology and HLA; Population Genetics and Signal Transduction L1: Immunology and HLA L2: Population genetics L3: Signal transduction |
||
| First decile publications | 4 | 260,8 |
| First quartile publications | 15 | 321,1 |
| Second quartile publications | 7 | 31,7 |
| Third quartile publications | 2 | 5,2 |
| Total publications (including those without IF) | 26 | 363,4 |
